about
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneExtended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unitProlonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantationCD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationTrends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisRegulation of acute graft-versus-host disease by microRNA-155.Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemiaAutologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchEffects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.Gastroparesis.Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte GlobulinHematopoietic stem cell transplantation in adults with acute myeloid leukemia.Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.How we approach patient evaluation for hematopoietic stem cell transplantation.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Rituximab maintenance versus retreatment in follicular lymphoma.Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasCurrent state of hematopoietic cell transplantation in CLL as smart therapies emerge.Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease.Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization.Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia.Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit.Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis.Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR.Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation.Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients.Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.Incidence and survival trends in mantle cell lymphoma.R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
P50
Q27024932-B638A9BB-7627-4499-8AA8-31B6663178A0Q28553703-BDCECF3B-C3CA-4580-BFF0-89E3DD6FC12DQ28950856-167ACE23-DE77-4F96-9C3E-60E6C4FBA004Q33383571-D4661694-EA31-43EA-B616-23CB2B049B0FQ33910076-BCB3A70C-B50B-4C97-AEBB-5BAFD9E2D501Q33968168-2E4A9E52-154D-4E14-A1AB-59F8006742F1Q34325329-C6E62912-D6BD-4676-90D4-B56C9D8C844FQ35172500-51066826-C951-4E88-9FF0-F830FBAB55DFQ36010229-ACE5DD97-6705-4457-B4C3-900554D38DB6Q36404698-8FA4066B-773D-4EE2-B4E1-5F2C94E6674EQ36557201-62DA6ACE-F2D4-4118-9F86-DE954AB0988BQ36570256-00DC8FC2-A33D-4300-8BAC-42DD65C86318Q36570651-C42435EC-D649-4109-B05F-28BA9156347AQ36775502-1B468FA5-B27D-4B33-9A0D-F8D940AB87A8Q36838087-A9045703-D8F7-4FE8-BFF6-D04BEE22A2EAQ37138148-51848502-3298-467E-96CE-9364BD939F6CQ37567632-57C32E69-1C15-4085-9130-360DE9AF3BBCQ37635642-44AA22D2-9C92-49A8-B99A-D0C3B64E8FF6Q37755957-618B2AB1-34D8-4029-A9F6-E74B1AE8A77DQ38045706-4B548B41-2A9F-4AF8-B9F8-5A29313773EFQ38050339-4EBCBBBE-AC88-4BDB-A141-587CB931E5ABQ38267567-F9175977-6614-40F1-A4A0-AD0F26769216Q38980975-10947BF0-F48B-43EB-A345-FAA07FBD10AEQ40190559-92DE71D5-0890-4EBC-8A3C-79F926A6B43EQ42133489-744880F8-8165-4AC3-9D7A-992BDE38F5C1Q43263263-B6B39958-3871-4C4A-9FF8-35EF7122881FQ43905021-B664AE94-DE08-471A-8EAC-F8116279EA47Q44809587-FA9DB45D-74E8-4F0E-831D-2C7EC7F1F83BQ44971790-36C967A4-7040-4304-BCEC-17B499403680Q44972278-B4A15C5B-28F1-4AA3-A63A-477C42940B8FQ44975461-D280F79F-03F9-4D59-B859-012AFCEE532EQ44979634-13C190FE-B49D-4D47-8305-2E07DBD9C49DQ45052132-75ED9A22-4E30-4244-9EA2-9F03921A56D7Q45407401-683CA6C6-248C-45F7-81E8-DD6969349071Q45870242-3B6EF8F2-EF64-4875-AEB9-38AC4ECF9A61Q46943067-912668B3-20C8-4401-9DD6-6337506E5FF3Q47567814-4EC79EE9-DF17-4513-A75A-AA31C5962383Q48231249-664805A7-88B0-4154-A99D-8ACD7D9ED1C9Q48371974-1DA399AD-FF2B-4BFF-B49E-7B02B96B9AEFQ50051516-BABEE4A0-FAFE-4A25-B67F-6BE063360316
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Mehdi Hamadani
@ast
Mehdi Hamadani
@en
Mehdi Hamadani
@es
Mehdi Hamadani
@nl
Mehdi Hamadani
@sl
type
label
Mehdi Hamadani
@ast
Mehdi Hamadani
@en
Mehdi Hamadani
@es
Mehdi Hamadani
@nl
Mehdi Hamadani
@sl
prefLabel
Mehdi Hamadani
@ast
Mehdi Hamadani
@en
Mehdi Hamadani
@es
Mehdi Hamadani
@nl
Mehdi Hamadani
@sl
P106
P1153
10739126800
P21
P214
7886155708706022580008
P31
P496
0000-0001-5372-510X
P734
P735
P7859
lccn-n2019184578